Form 8-K - Current report:
SEC Accession No. 0001437749-24-032705
Filing Date
2024-10-31
Accepted
2024-10-31 08:00:11
Documents
17
Period of Report
2024-10-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20241031_8k.htm   iXBRL 8-K 28791
2 EXHIBIT 99.1 ex_740672.htm EX-99.1 12630
7 nrx1n.jpg GRAPHIC 13705
8 nrxn.jpg GRAPHIC 5117
  Complete submission text file 0001437749-24-032705.txt   223558

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20241030.xsd EX-101.SCH 3872
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20241030_def.xml EX-101.DEF 13797
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20241030_lab.xml EX-101.LAB 18159
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20241030_pre.xml EX-101.PRE 13829
19 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241031_8k_htm.xml XML 4834
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241412501
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)